Evidence map›Paper›PMID 41019061›Full record

ReviewFrontiers in immunology2025

Activated PI3K-δ syndrome presenting with cervical lymphadenopathy in a pediatric patient: a case report and review of the literature.

Zhiwei Huang, Yaping Wang, Ruoying Wei, Hui Ding, Lian Du, Xiaomei Yang, Fu Li

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhiwei HuangPediatric Hematology and Oncology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
Yaping WangHematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, Shandong, China.
Ruoying WeiHematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, Shandong, China.
Hui DingHematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, Shandong, China.
Lian DuHematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, Shandong, China.
Xiaomei YangHematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, Shandong, China.
Fu LiHematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan Children's Hospital, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) is a primary immunodeficiency caused by gain-of-function mutations in the PIK3CD gene, leading to dysregulated immune responses. Clinical manifestations include recurrent infections, lymphoproliferation, and increased risk of malignancies. Due to its rarity and variable presentation, APDS is often misdiagnosed or diagnosed late. Case presentation: We report a case of a 12-year-old girl presenting with persistent cervical lymphadenopathy. Imaging studies revealed extensive lymph node involvement and splenomegaly. PET-CT raised suspicion for lymphoma. Histopathology of the excised lymph node demonstrated Epstein-Barr virus (EBV) latent infection Type III, while whole exome sequencing identified a pathogenic PIK3CD c.3061G>A (p.Glu1021Lys) heterozygous variant. This confirmed the diagnosis of APDS. Targeted therapy with sirolimus was initiated, leading to significant regression of lymphadenopathy and splenomegaly. The patient maintained good clinical status during follow-up. Conclusion: This case highlights the importance of genetic testing in pediatric patients with lymphoproliferative disease and unusual infection patterns. Early diagnosis of APDS enables personalized, targeted treatment and avoids overtreatment with cytotoxic agents.

Indexed as

Class I Phosphatidylinositol 3-KinasesLymphadenopathyPrimary Immunodeficiency DiseasesChildEpstein-Barr Virus InfectionsFemaleHerpesvirus 4, HumanHumansLymph NodesClass I Phosphatidylinositol 3-KinasesPIK3CD protein, humanAPDsEpstein-Barr virus (EBV)lymphadenopathypediatric immunodeficiencyPIK3CD

Identifiers

PMID41019061
PMCPMC12463851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.